Related Experiment Video
Updated: Mar 29, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
S-propranolol protected H9C2 cells from ischemia/reperfusion-induced apoptosis via downregultion of RACK1 Gene
Xiongfei Jia1, Li Zhang2, Xiaoqin Mao3
1Department of Clinical Laboratory, Kunming General Hospital Kunming, Yunnan, China.
Insights
S-propranolol protects heart cells from ischemia-reperfusion (I/R) injury by down-regulating RACK1. This mechanism reduces apoptosis, cytokine release, and oxidative stress, offering a potential therapeutic target for heart failure.
Area of Science:
- Cardiovascular Research
- Cellular Biology
- Pharmacology
Background:
- Ischemia-reperfusion (I/R) injury causes heart cell apoptosis and heart failure.
- The cardioprotective mechanism of propranolol remains unclear.
- RACK1 was previously identified as a target of S-propranolol in endothelial cells.
Purpose of the Study:
- To investigate the role of RACK1 in S-propranolol-mediated protection against I/R injury.
- To explore RACK1 as a potential therapeutic target for I/R-induced heart failure.
Main Methods:
- Constructed lentiviral vectors for RACK1 RNA interference (RNAi).
- Simulated I/R injury in H9C2 cells with and without S-propranolol treatment.
- Assessed cell apoptosis, cytokine/chemokine release, mitochondrial membrane potential (MMP), Ca(2+) concentration, and reactive oxygen species (ROS) using ELISA and flow cytometry.
- Measured caspase-3 activity, cytochrome c release, and JNK activation.
Main Results:
- RACK1 RNAi and S-propranolol treatment significantly protected I/R-injured cells from apoptosis.
- Both interventions attenuated cytokine/chemokine release, Ca(2+) overload, ROS production, and MMP reduction.
- RACK1 RNAi and S-propranolol reduced caspase-3 activity, cytochrome c release, and JNK activation.
Conclusions:
- RACK1 is a key mediator in S-propranolol's protective effects against I/R injury.
- Targeting RACK1 offers a promising therapeutic strategy for managing I/R-induced heart damage and heart failure.
Abstract:
Ischemia-reperfusion (I/R) injury can lead to apoptotic death of heart cells and subsequently heart failure. Propranolol is widely used in the management of cardiovascular disorders, but the mechanism is still unclear. Our previous studies showed that activated protein kinase C1 (RACK1) was significantly down-regulated in human umbilical vein endothelial cells by S-propranolol. RACK1 may be a target protein of S-propranolol during I/R. At present, we constructed a lentiviral expression vector for RNA interference (RNAi) of RACK1. The interference efficiency of the lentivirus was confirmed by RT-PCR and western blot. H9C2 cells infected with Lv-RACK1-shRNA or control were subjected to simulate I/R in the presence and absence of S-propranolol. The release of cytokines and chemokines was determined by ELISA assay. Flow cytometry was employed to determine mitochondrial membrane potential (MMP), Ca(2+) concentration, reactive oxygen species (ROS) production, and cell apoptosis. We found that RACK1 RNAi and S-propranolol treatment remarkably protected I/R injured cells from apoptosis via attenuating the release of cytokines and chemokines, Ca(2+) overload, ROS concentration, and MMP. Furthermore, RACK1 RNAi and S-propranolol, separately and in combination, significantly reduced caspase-3 activity, cytochrome c release and JNK activation. RACK 1 can be considered as a target for drug development.
